Randomised non-inferiority trial: 1600 mg versus 400 mg tablets of mesalazine for the treatment of mild-to-moderate ulcerative colitis.
G R D'HaensW J SandbornG ZouL W StittP J RutgeertsD GilgenV JairathP HindryckxLisa M ShackeltonM K VandervoortC E ParkerC MullerR K PaiO LevchenkoY MarakhouskiM HorynskiE MikhailovaN KharchenkoS PimanovBrian G FeaganPublished in: Alimentary pharmacology & therapeutics (2017)
Induction therapy with 3.2 mg mesalazine using two 1600 mg tablets once-daily was statistically and clinically non-inferior to a twice-daily regimen using four 400 mg tablets (NCT01903252).